BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28821581)

  • 21. Expression of S100 Protein in CD4-positive T-cell Lymphomas Is Often Associated With T-cell Prolymphocytic Leukemia.
    Aggarwal N; Pongpruttipan T; Patel S; Bayerl MG; Alkan S; Nathwani B; Surti U; Kitahara S; Chinthammitr Y; Swerdlow SH
    Am J Surg Pathol; 2015 Dec; 39(12):1679-87. PubMed ID: 26379148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
    Magro CM; Morrison CD; Heerema N; Porcu P; Sroa N; Deng AC
    J Am Acad Dermatol; 2006 Sep; 55(3):467-77. PubMed ID: 16908353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. "T-cell prolymphocytic leukemia (T-PLL), a heterogeneous disease exemplified by two cases and the important role of cytogenetics: a multidisciplinary approach".
    Tirado CA; Starshak P; Delgado P; Rao N
    Exp Hematol Oncol; 2012 Aug; 1(1):21. PubMed ID: 23211026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TCL1 is overexpressed in patients affected by adult T-cell leukemias.
    Narducci MG; Stoppacciaro A; Imada K; Uchiyama T; Virgilio L; Lazzeri C; Croce CM; Russo G
    Cancer Res; 1997 Dec; 57(24):5452-6. PubMed ID: 9407948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
    Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
    Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deregulated expression of TCL1 causes T cell leukemia in mice.
    Virgilio L; Lazzeri C; Bichi R; Nibu K; Narducci MG; Russo G; Rothstein JL; Croce CM
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3885-9. PubMed ID: 9520462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T-prolymphocytic leukemia: TCL1 or MTCP1 rearrangement is not mandatory to establish diagnosis.
    Fang H; Beird HC; Wang SA; Ibrahim AF; Tang Z; Tang G; You MJ; Hu S; Xu J; Li S; Yin CC; El Hussein S; Le N; Futreal PA; Bueso-Ramos C; Thakral B; Kadia TM; Thornton R; Little L; Gumbs C; Song X; Medeiros LJ; Wang W
    Leukemia; 2023 Sep; 37(9):1919-1921. PubMed ID: 37443196
    [No Abstract]   [Full Text] [Related]  

  • 28. Application of cross-species color banding (RxFISH) in the study of T-prolymphocytic leukemia.
    Espinet B; Solé F; Salido M; Lloveras E; Abella E; Besses C; Serrano S; Woessner S; Florensa L
    Haematologica; 2000 Jun; 85(6):607-12. PubMed ID: 10870117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia.
    Bergmann AK; Schneppenheim S; Seifert M; Betts MJ; Haake A; Lopez C; Maria Murga Penas E; Vater I; Jayne S; Dyer MJ; Schrappe M; Dührsen U; Ammerpohl O; Russell RB; Küppers R; Dürig J; Siebert R
    Genes Chromosomes Cancer; 2014 Apr; 53(4):309-16. PubMed ID: 24446122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of TCL1 in hematologic disorders.
    Roos J; Hennig I; Schwaller J; Zbären J; Dummer R; Burg G; Tobler A; Virgilio L; Croce CM; Fey MF; Borisch B
    Pathobiology; 2001; 69(2):59-66. PubMed ID: 11752899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia.
    Ruchlemer R; Parry-Jones N; Brito-Babapulle V; Attolico I; Wotherspoon AC; Matutes E; Catovsky D
    Br J Haematol; 2004 May; 125(3):330-6. PubMed ID: 15086413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of either the TCL1 oncogene, or transcripts from its homologue MTCP1/c6.1B, in leukaemic and non-leukaemic T cells from ataxia telangiectasia patients.
    Thick J; Metcalfe JA; Mak YF; Beatty D; Minegishi M; Dyer MJ; Lucas G; Taylor AM
    Oncogene; 1996 Jan; 12(2):379-86. PubMed ID: 8570215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delineation of clinical course, outcomes, and prognostic factors in patients with T-cell prolymphocytic leukemia.
    Rose A; Zhang L; Jain AG; Poovathukaran Babu A; Sokol L; Saeed H; Mo Q; Fan W; Zhang X
    Am J Hematol; 2023 Jun; 98(6):913-921. PubMed ID: 36964941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integration of conventional cytogenetics, comparative genomic hybridisation and interphase fluorescence in situ hybridisation for the detection of genomic rearrangements in acute leukaemia.
    McGrattan P; Campbell S; Cuthbert R; Jones FG; McMullin MF; Humphreys M
    J Clin Pathol; 2008 Aug; 61(8):903-8. PubMed ID: 18474541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translocation (14;14)(q11;q32) with simultaneous involvement of the IGH and CEBPE genes in B-lineage acute lymphoblastic leukemia.
    Han Y; Xue Y; Zhang J; Wu Y; Pan J; Wang Y; Shen J; Dai H; Bai S
    Cancer Genet Cytogenet; 2008 Dec; 187(2):125-9. PubMed ID: 19027493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recurrent loss, but lack of mutations, of the SMARCB1 tumor suppressor gene in T-cell prolymphocytic leukemia with TCL1A-TCRAD juxtaposition.
    Bug S; Dürig J; Oyen F; Klein-Hitpass L; Martin-Subero JI; Harder L; Baudis M; Arnold N; Kordes U; Dührsen U; Schneppenheim R; Siebert R
    Cancer Genet Cytogenet; 2009 Jul; 192(1):44-7. PubMed ID: 19480937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conventional karyotyping and fluorescence in situ hybridization: an effective utilization strategy in diagnostic adult acute myeloid leukemia.
    He R; Wiktor AE; Hanson CA; Ketterling RP; Kurtin PJ; Van Dyke DL; Litzow MR; Howard MT; Reichard KK
    Am J Clin Pathol; 2015 Jun; 143(6):873-8. PubMed ID: 25972330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrations of MYC are a common event in B-cell prolymphocytic leukemia.
    Flatley E; Chen AI; Zhao X; Jaffe ES; Dunlap JB; Pittaluga S; Abdullah S; Olson SB; Spurgeon SE; Fan G
    Am J Clin Pathol; 2014 Sep; 142(3):347-54. PubMed ID: 25125625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.
    Schrader A; Crispatzu G; Oberbeck S; Mayer P; Pützer S; von Jan J; Vasyutina E; Warner K; Weit N; Pflug N; Braun T; Andersson EI; Yadav B; Riabinska A; Maurer B; Ventura Ferreira MS; Beier F; Altmüller J; Lanasa M; Herling CD; Haferlach T; Stilgenbauer S; Hopfinger G; Peifer M; Brümmendorf TH; Nürnberg P; Elenitoba-Johnson KSJ; Zha S; Hallek M; Moriggl R; Reinhardt HC; Stern MH; Mustjoki S; Newrzela S; Frommolt P; Herling M
    Nat Commun; 2018 Feb; 9(1):697. PubMed ID: 29449575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Comprehensive Update on Molecular and Cytogenetic Abnormalities in T-cell Prolymphocytic Leukemia (T-pll).
    Delgado P; Starshak P; Rao N; Tirado CA
    J Assoc Genet Technol; 2012; 38(4):193-8. PubMed ID: 23183331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.